surmount-1 trial tirzepatide obesity without diabetes Effect of in trial. (BMI: body mass index; CI: ECO 2026: SURMOUNT-MAINTAIN proves tirzepatide

Understanding why you might not be losing weight on tirzepatide and whether persistent hunger on tirzepatide is affecting your progress can help you troubleshoot

On average, metformin leads to a weight loss of 5.5 to 8.8 lbs and a BMI reduction of 1 to 2 kg/m

Better fit for modest goals Standard tirzepatide dosing was designed for people with a BMI of 30 or higher

Using insulin secretion as a read-out in primary human islets provides a platform to interrogate this question in a system that is intimately linked to the glycemic benefits of tirzepatide

In conclusion, tirzepatide presents a compelling case as a breakthrough treatment for addressing body weight concerns in conjunction with metabolic health